Free course · 12 modules
GLP-1 Longevity Course
What GLP-1 medications can — and can't — do for healthy aging. Short, evidence-based lessons that separate proven benefits from hype.
Module 1
What Exactly Is a GLP-1?
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. It belongs to a family called incretins, which help your body handle a meal.
What natural GLP-1 does
- • Increases insulin release, but only when blood sugar is elevated (glucose-dependent)
- • Reduces glucagon, a hormone that raises blood sugar
- • Slows how quickly the stomach empties
- • Acts on appetite and fullness pathways in the brain
Your own GLP-1 lasts only minutes. GLP-1 receptor agonist medications are engineered to activate the same receptor for far longer, which is why their effects on appetite and blood sugar are much stronger.
The major medications
- • Semaglutide — Ozempic / Wegovy
- • Liraglutide — Victoza / Saxenda
- • Dulaglutide — Trulicity
- • Tirzepatide — Mounjaro / Zepbound (technically a dual GIP/GLP-1 receptor agonist)
Longevity takeaway
GLP-1 drugs weren't developed as longevity therapies. The interest emerged because the conditions they improve — obesity, diabetes, cardiovascular disease and kidney disease — are major drivers of disability and early death.
Module 2
GLP-1s and the Biology of Aging
It's important to separate how a drug might work (mechanism) from what it has actually been proven to do (outcomes).
Proposed longevity pathways
- • Less visceral (deep belly) fat
- • Better insulin sensitivity and blood sugar control
- • Lower cardiometabolic risk
- • Lower markers of systemic inflammation
- • Improved blood pressure and lipid-related risk factors
- • Fewer cardiovascular events in selected populations
- • Potential kidney protection
Healthspan ≠ lifespan
A drug can reduce disease risk without having been shown to slow biological aging itself.
Evidence level
- • Strong: obesity, diabetes, cardiovascular and kidney outcomes in specific populations
- • Emerging: inflammation, liver disease and some other age-related disease pathways
- • Unproven: general anti-aging, slowing biological aging, increasing maximum lifespan, or extending lifespan in otherwise healthy people
Module 3
Weight, Visceral Fat and Metabolic Health
This is the foundation of the longevity argument. Visceral fat — the fat around your organs — matters far more for health than simply looking thinner.
Excess visceral fat is associated with
- • Insulin resistance
- • Type 2 diabetes
- • Cardiovascular disease
- • Fatty liver disease
- • Chronic inflammation
- • Sleep apnea
- • Mobility limitations
In a STEP 1 body-composition substudy, people taking semaglutide lost about 15% of body weight, with roughly 19% less total fat mass and 27% less visceral fat.
The trade-off
Lean body mass also fell by about 9.7% in that substudy — even though lean mass rose as a share of total body weight. That leads directly to the most important module in this course.
Unlock the full course — free
Continue with Modules 4–12
- 🔒 4. The Muscle Problem: Losing Fat Without Becoming Frail
- 🔒 5. GLP-1s and Cardiovascular Longevity
- 🔒 6. Diabetes Prevention and Metabolic Longevity
- 🔒 7. Kidney Protection
- 🔒 8. Brain Health: Exciting Hypothesis Meets Reality
- 🔒 9. Sleep, Sleep Apnea and Healthy Aging
- 🔒 10. Risks, Side Effects and Who Should Be Careful
- 🔒 11. The Longevity Lifestyle While Taking a GLP-1
- 🔒 12. Are GLP-1s Actually Longevity Drugs?
Educational information for adults, not medical advice. This course does not diagnose conditions, determine eligibility or recommend treatment. Talk with your healthcare professional about your own situation.
